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Abstract: In this assay, a selective, simplistic and sensitive new online heart-cutting Liquid Chroma-
tographic analysis method was developed for the quantification of linezolid in human serum. The new 
method allows to the quantification of linezolid in serum without complicated sample preparation. Before 
analysis, the samples were mixed with methanol and filtered. Separations were carried out with following 
systems; 1st dimension is a system consisting of 2.1 x 50 mm Biphenyl pre-separation column with  
acetonitrile and 0.03 M o-phosphoric acid solution mixture (15:85) as mobile phase and the 2nd dimen-
sion is a system consisting of 4.6 x 150 mm Pentafluorophenyl propyl separating column with acetonitrile 
and 0.03 M o-phosphoric acid solution mixture (25:75) as mobile phase. Two systems were connected via 
a 6-port valve having 0.2 mL loop and separations were carried out continuously during injections. For 
both systems, 250 nm has been selected as detection wavelength. The concentration range of 0.5-20 
μg/mL was found as linear calibration curve. The new method was successfully applied for the  
quantification of linezolid in human serum samples collected from a volunteer who has received 600 mg 
linezolid orally. 
Keywords: Linezolid, Online Heart-Cutting Liquid Chromatography, UV Detection, Human Serum, Method Development 
&Validation. 
1. INTRODUCTION 
Linezolid, (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]- 
2-oxo-5-oxazolidinyl] methyl]-acetamide (Fig. (1)) is a syn-
thetic antibacterial agent of the oxazolidinone class which 
active against most Gram-positive bacteria that cause dis-
ease, including streptococci, vancomycin-resistant entero-
cocci (VRE), and methicillin-resistant Staphylococcus 
aureus (MRSA) [1]. Linezolid is rapidly and extensively 
absorbed after oral administration. Maximum plasma line-
zolid concentrations are usually achieved between 1 and 2 
hours after oral administration [2]. 
Liquid chromatographic methods involving different 
sample preparation technique, i.e. protein precipitation [3-9], 
liquid-liquid extraction [10, 11], solid-phase extraction [12, 
13], microdialysis [5] and Dried Blood Sample [14] were 
performed for linezolid analyzing in biological samples. In 
this study, a new heart-cutting liquid chromatographic (LC) 
method was presented without any extraction technique in 
serum samples by ultraviolet (UV) detection. Online heart-
cutting methods has some advantage over other separation 
methods like comprehensive separation, excellent resolution 
and minimize the sample losses [15-18].  
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Fig. (1). Chemical structure of Linezolid.  
 
The purpose of the current study is to develop a selective, 
simplistic and sensitive online heart-cutting LC method with 
UV detection for the quantification of linezolid in human 
serum samples. The proposed method was also successfully 
applied to the quantification of linezolid in serum samples 
collected from a volunteer who has received 600 mg line-
zolid orally. 
2. EXPERIMENT 
2.1. Chemicals and Solutions  
Linezolid and its formulation (Zyvoxid Film Tablet® 600 
mg of linezolid) were supplied from Pfizer laçları Limited 
	ti. (Istanbul, Turkey). Ultrapure water was obtained from 
water purification system (ELGA Purelab Option-Q DV 25 
(UK)) and the chemicals and solvents were of gradient and 
analytical grade.  
The 0.5 mg/mL concentration of linezolid was prepared 
in water (Stock solution 1). The concentrations of 2.5, 5, 15, 
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25, 50 and 100 μg/mL of linezolid solutions for spiked se-
rum study were prepared by diluting the first stock solution 
with same solvent (Stock solutions 2). The standard solu-
tions of linezolid were prepared at different concentrations 
(0.5, 1, 3, 5, 10 and 20 μg/mL) diluted with water from sec-
ond stock solutions. 
2.2. Chromatographic System 
The separations were carried out using a Shimadzu LC-
20A chromatography system (Kyoto, Japan). First chroma-
tographic system was consisted of a pump (LC-20AT), a 
vacuum degasser (DGU-20A5), an autosampler (SIL-20AC), 
a column oven (CTO-20A), a 6-port valve (FCV-12AH, hav-
ing a 0.2 mL steel loop) and a UV detector (SPD-20A). Sec-
ond chromatographic system was consisted of a pump (LC-
20AD), a vacuum degasser (DGU-20A5), a column oven 
(CTO-20A, 1st system oven) and a PDA detector (SPD-
M20A) and two systems were connected via 6-port valve 
which controlled by a system software (LC Solution Version 
1.24). LC data were collected and processed by the same 
system software. First chromatographic system is consisting 
of 2.1 x 50 mm Biphenyl pre-separation column with aceto-
nitrile and 0.03 M o-phosphoric acid solution mixture 
(15:85) as mobile phase and the 2nd chromatographic system 
is consisting of 4.6 x 150 mm Pentafluorophenyl propyl 
separating column with acetonitrile and 0.03 M o-phosphoric 
acid solution mixture (25:75) as mobile phase. Detection 
wavelength has been selected as 250 nm for both systems. 
The scheme of the system for two valve positions described 
was provided in Fig. (2). 
2.3. 2D System Parameters  
Some special parameters about 2D-LC system were in-
vestigated like “switching time for valve”, “sample volume 
in loop” and “differentiation on pressure”. At first, time for 
rotation of the 6-port valve from 0 position to 1 was investi-
gated. Some assays were performed in order to establish the 
moment where the amount of analyte reached the highest 
level in the loop. For this purpose, linezolid within the sam-
ple loop was sent to the 2nd system by switching the valve 
from position 0 to 1 at time points 2.0, 2.1, 2.2, 2.3, 2.4 and 
2.5 minutes representing the completion of linezolid peak 
obtained after injection of standard substance in the 1st sys-
tem. Switching time was selected based on the evaluation of 
peak areas resulting from the analysis of this analyte.  
After the selection of valve rotation time, different sam-
ple volumes for loop were tested. Optimum volume of the 
sample was determined to enable the delivery of the linezolid 
with matrix in the 1st system mobile phase to the 2nd sys-
tem. In this assay, theoretically the recovery of the analyte 
proportionally increased with the increasing volume of the 
loop. However, increasing volume of the loop led to band 
broadening in the 2nd system. Based on these findings, vol-
ume of the loop should be adjusted to have an appropriate 
recovery with sharp peaks. In order to find optimum loop 
volume, loops having different volumes of 0.1, 0.2, 0.5 and 1 
mL were set in the 6-port valve where the most suitable vol-
ume for sample loop was selected according to analysis re-
sults of standards and serum samples in described analytical 
conditions.  
 
Fig. (2). The scheme of the online heart-cutting LC system for two valve positions. 
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Ultimately, during the analysis, changing the baseline 
and differentiation in pressure of the system as a result of 
switching the 6-port valve from position 0 to 1 were assayed. 
2.4. Sample Preparation  
5 mL venous blood samples collected from a healthy 
volunteer were transferred into test tubes and within 2 h from 
collection the samples were centrifuged for 15 min at 
1400g. The supernatant was placed into polypropylene 
tubes and stored at 20 °C until analysis.  
0.1 mL linezolid solutions were added 0.5 mL of super-
natant (serum), to obtain final concentration as 0.1-5 μg/mL. 
The spiked serum samples were vortexed for approximately 
10 s and following that 1 mL of methanol was added and 
vortexed for 1 min. Each sample was filtered with 0.45 m 
and 0.2 m Nylon filter, respectively, and 80 μL filtrate were 
injected into the LC system. 
2.5. Method Validation 
The developed method was validated with respect to de-
scribed parameters in guidelines such as accuracy, selectiv-
ity, recovery, precision, sensitivity, the calibration curve, 
reproducibility, carry over and stability of analyte [19].  
The selectivity of the method was tested by both purity 
control of the linezolid peak using PDA detector and blank 
serum study. 
Serum calibration standards were prepared at six levels 
by spiking 0.5 mL of human serum with the 0.5-20 μg/mL 
concentrations of linezolid. The spiked samples were pre-
pared as previously described in Sample Preparation section 
and a portion of 80 μL was injected into the LC system. The 
calibration curves were generated by means of the least-
square method using the analyte peak areas versus the corre-
sponding concentrations of the linezolid (as g/mL). The 
slope (a), intercept (b) and coefficients of determination (r2), 
which were used to determine the concentration of linezolid 
in the serum samples, were obtained from the linear regres-
sion analysis of the calibration curves. The limit of quantita-
tion (LOQ) was defined as the lowest concentration level 
giving a chromatographic response with acceptable 
coefficient of variation. 
The absolute recovery was performed for three concen-
tration level as 0.5, 10 and 20 g/mL. For this purpose, di-
viding the mean peak area from spiked serum samples (ex-
tracted analyte) by mean peak area of standard solutions (un-
extracted analyte). The absolute recovery was calculated 
using the equation: absolute recovery = (response peaks of 
extracted/unextracted)  100. 
The precision and accuracy of the developed method 
were examined with regard to intra-day precision (repeatabil-
ity) and inter-day precision (intermediate precision). For this 
purpose, spiked serum samples at three different concentra-
tion levels (0.5, 10 and 20 g/mL) of linezolid were analyzed 
six times a day and six successive days in triplicate injec-
tions. The precision and the accuracy were calculated as rela-
tive standard deviation (RSD) and relative mean error 
(RME), respectively. Precision and accuracy values covering 
± 15% of the actual range of experimental concentrations 
were considered acceptable. The prepared serum samples 
with the procedure provided in the Sample Preparation sec-
tion were injected into the LC system. Accuracy and preci-
sion were calculated from the data obtained and the results 
provided as mean ± SD, RSD and RME. 
The stability of linezolid in serum samples was tested at 
0.5 g/mL (low) and 20 g/mL (high) concentrations for 
following conditions; in the autosampler (+4 °C for 12 h), 
after three freeze–thaw cycles, on storage (20 °C for 14 
days).  
2.6. Application of the Method 
The validated method was used for the quantification of 
linezolid in human serum samples obtained from 43 years 
old a healthy volunteer’s blood (77 kg, 178 cm height, 
Sagirli O., researcher of this study). After administering sin-
gle oral dose of 600 mg of linezolid, venous blood samples 
were collected into tubes at 1.0-hour post dosing. The serum 
samples were obtained from venous blood as previously de-
scribed in Sample Preparation section and the samples were 
stored at -20 °C until analysis. 
3. RESULTS  
3.1. Chromatographic System 
For this purpose, various type of analytical columns were 
assayed especially for 2nd system like C8, CN, C18, PFPP, 
phenyl and biphenyl using different mobile phases. The 
chromatographic conditions obtained the isole and sharp 
linezolid peak was observed as follows; 
Column (1st System): Restek Pinnacle DB BiPh (2.1 x 50 
mm, 5 μm I.D.) at 30 °C 
Mobile phase (1st System): Acetonitrile and 0.030 M o-
phosphoric acid solution mixture (15:85) with 0.5 mL/min 
flow rate 
Column (2nd System): Restek Allure PFPP (4.6 x 150 
mm, 5 μm I.D.) at 30 °C 
Mobile phase (2nd System): Acetonitrile and 0.03 M o-
phosphoric acid solution mixture (25:75) with 1 mL/min 
flow rate 
For both systems, 250 nm was selected as detection 
wavelength. Under this conditions, retention times were 
found as 1.9 and 7.6 min for the 1st and 2nd system, respec-
tively (Fig. (3)). 
3.1.1. Switching Time for Valve 
For the selection of switching time, FCV-12A valve was 
rotated from position 0 to 1 at following time points, 2.0, 2.1, 
2.2, 2.3, 2.4 and 2.5 minutes. Thus, 0.2 mL portion of 1st 
separation was sent to the 2nd system and peak areas ob-
tained from 2nd chromatographic separation was investi-
gated. Results indicated that peak areas were maximum 
when the valve rotation time was selected as 2.2 minute and 
this point was selected as valve switching time. 
3.1.2. Loop Volume 
The volume of the loop was investigated to enable the 
delivery of the analyte to the 2nd system. For this purpose, 
various volume of loops (0.1, 0.2, 0.5 and 1 mL) were tested 
according to peak areas and band broadening. The results 
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show that, the optimum analyte peaks were obtained with 
loop volume of 0.2 mL. 
3.1.3. Differentiation on Pressure 
Resulting from switching the 6-port valve, differences at 
baseline and changes the system pressure were investigated. 
As a result, it was found that the mixing the mobile phases at 
the transition between the systems did not have an impact on 
linezolid peak (Fig. (3B) and (3C)). System pressure was 
monitored when the 6-port valve was rotated. The pressure 
reached a stable level rapidly and stayed constant during the 
period of analysis. 
3.2. Method Validation 
The all analyte peaks were found as pure according to the 
peak purity index values obtained from PDA detector (mean 
peak purity index value was 0.9999981) and the blank serum 
studies. 
The calibration curves were constructed using peak areas 
obtained versus the corresponding concentrations of the line-
zolid at the range of 0.5-20 μg/mL in human serum. The 
mean linear regression equation was calculated as y = 4564 x 
- 4602.7 (r2 = 0.9993) from calibration curves, where y rep-
resents the peak area of linezolid, x represents the serum 
concentrations of linezolid. The standard errors (SE) of the 
slope and intercept were found as 127.8 and 472.1, respec-
tively. The coefficients of determination values ranged from 
0.9982 to 0.9995, proving good linearity of the method. The 
LOQ measured with acceptable precision and accuracy under 
the described conditions for the developed method in serum 
was 75 ng/mL for which the RSD value was less than 20%. 
Tree different concentration levels (0.5, 10 and 20 
g/mL) of linezolid were spiked at the blank human serum 
for absolute recovery study. As a result, absolute recovery of 
linezolid for serum samples was found as 91.43% (Table 1). 
Results of precision studied within the same day analyti-
cal run and analytical runs performed in different days at 3 
different concentrations of linezolid representing low, me-
dium and high concentrations are provided in Table 2 and 
Table 3, respectively. RSD values were calculated to be in 
 
Fig. (3). (A) Chromatograms of the blank serum sample, serum sample spiked with linezolid (1.0 μg/mL) and standard linezolid solution (1.0 
μg/mL) at the 1st system. 
(B) Chromatograms of the blank serum sample and serum sample spiked with linezolid (1.0 μg/mL) at the 2nd system. 
(C) Chromatograms of the blank serum sample and healthy volunteer serum sample (obtained from 1.0 h after oral administration of 
Zyvoxid) at the 2nd system. 
Online Heart-Cutting Liquid Chromatographic Analysis Current Pharmaceutical Analysis, 2017, Vol. 13, No. 1    9 
the interval of 1.01-2.26 for intraday precision and 1.28-3.54 
for inter-day precision. RME values were calculated to be 
within the interval of 0.51-1.41 and 0.76-1.93 for intra- and 
inter-day assay, respectively. The findings of precision and 
accuracy assay met the acceptance criteria established in 
guidelines for bioanalytical studies. According to stability 
study findings, linezolid was found to be stable under tested 
conditions in the current study (maximum deviation was 
found to be 2.97%).  
 
3.3. Application of the Method 
The developed method was applied for the quantification 
of linezolid in human serum samples. The chromatographic 
graph resulting from analytical run of a biological sample of 
a healthy volunteer who has been given a single dose of 
Zyvoxid (having 600 mg of linezolid) film tablet is provided 
in Fig. (3C). Calculated linezolid concentration (17.21 ± 
0.48 μg/mL) based on analysis is consistent with literature 
data [20]. 
Table 1. Extraction recovery of Linezolid from serum. 
Added concentration (μg/mL) Found Concentration (μg/mL) ± SD Recovery (%) RSD (%) 
0.5 0.45 ± 0.012 90.33 2.59 
10.0 9.21 ± 0.129 92.05 1.40 
20.0 18.38 ± 0.308 91.91 1.68 

Table 2. Intra-day precision values. 
 Added Concentration (μg/mL) 
 0.5 10.0 20.0 
Found Concentration 
(μg/mL) 
0.478 
0.499 
0.485 
0.501 
0.507 
0.487 
9.73 
9.85 
9.97 
9.89 
9.98 
10.14 
19.90 
20.04 
19.75 
20.00 
20.12 
19.58 
Mean 
SD 
RSD (%) 
RME (%) 
0.493 
0.011 
2.26 
-1.43 
9.93 
0.139 
1.40 
-0.73 
19.90 
0.201 
1.01 
-0.51 

Table 3. Inter-day precision values. 
 Added Concentration (μg/mL) 
 0.5 10.0 20.0 
Found Concentration 
(μg/mL) 
0.495 
0.491 
0.462 
0.504 
0.510 
0.480 
9.76 
10.02 
9.98 
9.99 
9.62 
10.11 
19.77 
20.01 
19.92 
19.88 
20.12 
19.39 
Mean 
SD 
RSD (%) 
RME (%) 
0.490 
0.0174 
3.54 
-1.93 
9.91 
0.184 
1.86 
-0.87 
19.85 
0.254 
1.28 
-0.76 
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4. DISCUSSION 
As mentioned above, various liquid chromatographic 
methods were referred for the quantification of linezolid in 
human biological fluids. Some of these methods including 
laboring extraction procedures like liquid-liquid extraction or 
solid phase extraction and special sample preparation tech-
niques like microdialysis or high-cost instruments. The ma-
jor advantage of the developed method over all reported 
methods is simplicity of sample cleanup procedure. The se-
rum samples were mixed with methanol and filtered just 
before the analysis. The proposed method is sensitive and 
reliable and also having simplistic sample preparation with 
excellent separation technique without internal standard. The 
new heart-cutting LC system was designed based on a Shi-
madzu LC-20A model liquid chromatography system. Sec-
ond separation was carried out via only one 6-port valve hav-
ing 0.2 mL sample loop. Proposed heart-cutting approach 
enables automatic analysis through non complicated sample 
treatment procedure having a lower total cost and shorter 
total operation time compared to widely used analytical 
setup. Unlike the currently used classical 2D LC set up the 
developed approach needs shorter run time in the 1st system 
column and longer run time in the second column. The new 
method was validated current ICH Guidelines preferring 
optimized chromatographic conditions and 2D system pa-
rameters and used for the quantification of linezolid in serum 
samples obtained from a volunteer.  
5. CONCLUSION 
This is the first method for the quantification of linezolid 
in human serum by online heart-cutting LC in literature. De-
veloped and validated method was successfully applied for 
the quantification of linezolid in serum samples from 600 mg 
single dose treatment of 43 years old healthy volunteer. Re-
sults demonstrated that the developed method is applicable 
for the quantification of linezolid in human serum for phar-
macokinetic studies.  
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